Brief: Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
14/01/2025 13:00
Jan 14 (Reuters) - Emergent BioSolutions Inc EBS.N :
* EMERGENT BIOSOLUTIONS GAINS EXCLUSIVE COMMERCIAL RIGHTS TO
KLOXXADO® (NALOXONE HCI) NASAL SPRAY FROM HIKMA PHARMACEUTICALS
* EMERGENT BIOSOLUTIONS: HIKMA WILL CONTINUE TO MANUFACTURE
KLOXXADO NASAL SPRAY 8 MG TO MAINTAIN DISTRIBUTION AND
AVAILABILITY
Source text: ID:nGNX4qQ5Yx
Further company coverage: EBS.N
((Reuters.Briefs@thomsonreuters.com;))